Enrollment criteria
diabetic retinopathy, AMD, hereditary retinal degeneration
DIABETIC RETINOPATHY, DEGENERATION, MACULAR NEOVASCULARIZATION, SECONDARY, MACULAR ATROPHY
Candidates with GA ≥ 50 years of age with BCVA between 20/25 and 20/320 in the study eye were eligible for enrollment. The selection of the study eye was based on the ophthalmic inclusion and exclusion criteria. In cases where both eyes of a candidate were eligible, the choice of the study eye was at the investigator’s discretion. The GA lesion had to be non–center point involving, and, in part, within 1.5 mm from the foveal center. Total lesion area had to be between 2.5 and 17.5 mmCandidates were excluded if they had macular atrophy secondary to any condition other than AMD in either eye (e.g., myopic degeneration or hereditary retinal degeneration). Candidates must not have received any prior treatment for AMD or any prior IVT treatment for any indication in either eye, apart from oral vitamins or mineral supplements. The proposed study eye was also excluded if any subtype of macular neovascularization (MNV) was detected in either eye, or if any ocular condition was present in the study eye that could progress during the study and potentially affect central vision or otherwise act as a confounding factor, or if there was any sign of diabetic retinopathy in either eye.